Breaking Down Axsome Therapeutics: 19 Analysts Share Their Views
Axsome Therapeutics Is Maintained at Outperform by RBC Capital
RBC Lifts Price Target on Axsome Therapeutics to $131 From $130, Keeps Outperform Rating
The Five-year Returns Have Been Enviable for Axsome Therapeutics (NASDAQ:AXSM) Shareholders Despite Underlying Losses Increasing
Express News | Axsome Therapeutics: Fifth Amendment to Increase Tranche 3 Commitment From $75 to $80 Mln
Express News | Axsome Therapeutics: On September 30 Entered Into Fifth Amendment to Its Loan & Security Agreement Dated Sept 25, 2020
Wells Fargo Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $140
Buy Rating Justified for Axsome Therapeutics Amidst Strong Market Opportunities and Promising Trial Outcomes
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Establishment Labs Holdings (ESTA), Alkermes (ALKS) and Axsome Therapeutics (AXSM)
Axsome Therapeutics Presents Data From Multiple Programs at Sleep Europe 2024
Axsome Therapeutics: A Strong Buy on Auvelity's Robust Market Performance and Growth Prospects
RBC Capital Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $130
RBC Capital analyst Leonid Timashev maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 50.
RBC Capital Sticks to Their Buy Rating for Axsome Therapeutics (AXSM)
TD Cowen Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $120
TD Cowen analyst Joseph Thome maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $120.According to TipRanks data, the analyst has a success rate of 44.9%
Axsome Therapeutics Insider Sold Shares Worth $1,005,871, According to a Recent SEC Filing
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $106
Mizuho Securities analyst Graig Suvannavejh maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $106.According to TipRanks data, the analyst has a success
Analysts Expect Breakeven For Axsome Therapeutics, Inc. (NASDAQ:AXSM) Before Long
Axsome Therapeutics (AXSM) Gets a Buy From Cantor Fitzgerald
Needham Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $130
Needham analyst Ami Fadia maintains $Axsome Therapeutics(AXSM.US)$ with a buy rating, and maintains the target price at $130.According to TipRanks data, the analyst has a success rate of 46.2% and a